Latest period
$3.83B
YoY change
+1.2%
5Y CAGR
+1.6%
Peak year (2022)
$24.94B
Latest annual
$19.03B
Operating Cash Flow history chart for AbbVie (ABBV) from 2009 to 2025
Latest: $19.03B
Operating Cash Flow growth chart for AbbVie (ABBV) from 2009 to 2025
Latest: +1.2%
Operating Cash Flow history table for AbbVie (ABBV) from 2009 to 2025
| 2025 | $19.03B | +1.2% | +$224.00M | ||
| 2024 | $18.81B | -17.7% | −$4.03B | ||
| 2023 | $22.84B | -8.4% | −$2.10B | ||
| 2022 | $24.94B | +9.5% | +$2.17B | ||
| 2021 | $22.78B | +29.5% | +$5.19B | ||
| 2020 | $17.59B | +32.0% | +$4.26B | ||
| 2019 | $13.32B | -0.8% | −$103.00M | ||
| 2018 | $13.43B | +34.8% | +$3.47B | ||
| 2017 | $9.96B | +41.5% | +$2.92B | ||
| 2016 | $7.04B | -6.6% | −$494.00M | ||
| 2015 | $7.54B | +112.3% | +$3.99B | ||
| 2014 | $3.55B | -43.4% | −$2.72B | ||
| 2013 | $6.27B | -1.2% | −$78.00M | ||
| 2012 | $6.34B | +1.6% | +$98.04M | ||
| 2011 | $6.25B | +25.5% | +$1.27B | ||
| 2010 | $4.98B | -7.3% | −$391.34M | ||
| 2009 | $5.37B | — | — |
- 2025$19.03B+1.2%
- 2024$18.81B-17.7%
- 2023$22.84B-8.4%
- 2022$24.94B+9.5%
- 2021$22.78B+29.5%
- 2020$17.59B+32.0%
- 2019$13.32B-0.8%
- 2018$13.43B+34.8%
- 2017$9.96B+41.5%
- 2016$7.04B-6.6%
- 2015$7.54B+112.3%
- 2014$3.55B-43.4%
- 2013$6.27B-1.2%
- 2012$6.34B+1.6%
- 2011$6.25B+25.5%
- 2010$4.98B-7.3%
- 2009$5.37B—
Operating Cash Flow values are taken from AbbVie's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at AbbVie (ABBV)
Operating Cash Flow for AbbVie (ABBV): headline value $3.83B · YoY +1.2%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual operating cash flow for AbbVie (ABBV) came in at $19.03B – edged up 1.2% year-over-year.
AbbVie operating cash flow compound annual growth for the 2020–2025 (5 years) window is +1.6%, with mixed annual results across the window.
AbbVie operating cash flow peaked at $24.94B in 2022; the latest annual figure is $19.03B in 2025 (23.7% below peak).
2022 marks the peak operating cash flow at $24.94B, with the historical low of $3.55B recorded in 2014.
AbbVie Operating Cash Flow by Year
AbbVie Operating Cash Flow 2025: $19.03B
AbbVie operating cash flow in 2025 was $19.03B, edged up 1.2% from 2024.
AbbVie Operating Cash Flow 2024: $18.81B
2024's operating cash flow for AbbVie came in at $18.81B, declined 17.7% below 2023.
AbbVie Operating Cash Flow 2023: $22.84B
AbbVie posted operating cash flow of $22.84B in 2023, declined 8.4% below 2022.
AbbVie Operating Cash Flow 2022: $24.94B
In 2022, AbbVie reported operating cash flow of $24.94B, grew 9.5% from 2021. This figure represents the highest annual value in the available history.
AbbVie Operating Cash Flow 2021: $22.78B
AbbVie operating cash flow in 2021 was $22.78B.
See more financial history for AbbVie (ABBV).
Sector peers by Operating Cash Flow
Healthcare peers of AbbVie (ABBV), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B | |
| $7.82B |
- $24.53B
- $19.70B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation